Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 19/20 | 0.66 |
| ▸ | TCF7L2 | Q9NQB0 | 19/20 | 0.66 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3641690 | 0.88 | CTNNB1 (0.76) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL3644755 | 0.87 | HRH4 (0.55) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL3639927 | 0.87 | CTNNB1 (0.76) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL3642983 | 0.86 | CTNNB1 (0.68) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL29143528 | 0.85 | CTNNB1 (0.59) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL3779862 | 0.85 | EHMT2 (0.68) | CTNNB1TCF7L2HRH4 | |
| Hydrochloric Acid SCHEMBL3637894 | 0.84 | EHMT2 (0.67) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL3640774 | 0.81 | APP (0.63) | CTNNB1TCF7L2HRH4 | |
| SCHEMBL4179590 | 0.80 | CTNNB1 (1.00) | CTNNB1TCF7L2 | |
| SCHEMBL4178577 | 0.80 | CTNNB1 (1.00) | CTNNB1TCF7L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101784276-A | Use of compounds for the preparation of antituberculosis agents | SUMMIT CORP PLC | 2010-07-21 | — | — | CN | claimed |
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | disclosed |
| CN-101784276-A | Use of compounds for the preparation of antituberculosis agents | SUMMIT CORP PLC | 2010-07-21 | — | — | CN | disclosed |
| EP-2173346-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | Summit Corporation Plc (GB) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009001060-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | SUMMIT CORPORATION PLC (GB) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | TPX2, DCXR, RRM2 | CTNNB1 4434/4885TCF7L2 1383/4885HRH4 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.